Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen
K. Brown et al., Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen, CARCINOGENE, 20(10), 1999, pp. 2011-2016
determined by P-32-postlabelling, in the livers of rats given tamoxifen and
the N-demethylated metabolites N-desmethyltamoxifen and N,N-didesmethyltam
oxifen. Results show that after 4 days treatment (0.11 mmol/kg i.p,), simil
ar levels of DNA damage were seen after treatment with either tamoxifen or
N-desmethyltamoxifen [109 +/- 40 (n = 3) and 100 +/- 33 (n = 4) adducts/10(
8) nucleotides, respectively], even though the concentration of tamoxifen i
n the livers of tamoxifen-treated rats was about half that of N-desmethylta
moxifen in the N-desmethyltamoxifen-treated animals (51 +/- 16 and 100 +/-
8 nmol/g, respectively). Administration of N,N-didesmethyltamoxifen to rats
resulted in a S-fold lower level of damage (19 adducts/10(8) nucleotides,
n = 2), Following P-32-postlabelling and HPLC, hepatic DNA from rats treate
d with tamoxifen and its metabolites showed distinctive patterns of adducts
. Treatment of rats with N,N-didesmethyltamoxifen gave a major product that
co-eluted with one of the minor adduct peaks seen in the livers of rats gi
ven tamoxifen, Following dosing with N-desmethyltamoxifen, the major produc
t co-eluted with one of the main peaks seen following treatment of rats wit
h tamoxifen. This suggests that tamoxifen can be metabolically converted to
N-desmethyltamoxifen prior to activation. However, analysis of the P-32-po
stlabelled products from the reaction between alpha-acetoxytamoxifen and ca
lf thymus DNA showed two main peaks, the smaller one of which (similar to 1
5% of the total) also co-eluted with that attributed to N-desmethyltamoxife
n, This indicates that N-desmethyltamoxifen and N,N-didesmethyltamoxifen ar
e activated in a similar manner to tamoxifen leading to a complex mixture o
f adducts, Since an HPLC system does not exist that can fully separate all
these 32P-postlabelled adducts, care has to be taken when interpreting resu
lts and determining the relative importance of individual adducts and the m
etabolites they are derived from in the carcinogenic process.